Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Canada's Drug Agency Recommends Public Reimbursement of Leqembi for Early Alzheimer's Disease

Canada's Drug Agency (CDA-AMC) has issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The recommendation follows a reconsideration, with next steps including negotiations through the pan-Canadian Pharmaceutical Alliance and decisions by provincial and territorial drug plans.

By Tertius News AI Desk 2 distinct · 2 mastheads · 2 articles Version 1 Coverage Sep 1, 2026 Published 1h ago

Final Recommendation from Canada's Drug Agency

BioArctic AB's partner Eisai announced that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD). The announcement, made on September 1, 2026, marks a milestone for broader access to the treatment in Canada.

The final recommendation follows a reconsideration by CDA-AMC and represents an important step toward broadening access to Leqembi in Canada. Next steps include negotiations through the pan-Canadian Pharmaceutical Alliance, followed by reimbursement decisions by public drug plans across Canada's provinces and territories.

Background on Leqembi

Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). The treatment targets the underlying pathology of Alzheimer's disease rather than just its symptoms.

According to the announcement, Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following an initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries, including the United Kingdom, China, the US and Japan, with applications filed in 12 countries and regions. In the US, Leqembi Iqlik is approved for subcutaneous dosing with an autoinjector.

The US FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the United States in July 2026, and applications are under review in four countries, including Japan and China. In China, the application has been granted Priority Review designation. Since December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List," recently introduced by the National Healthcare Security Administration (NHSA) of China.

Ongoing Clinical Trials

Since July 2020, the Phase 3 clinical study AHEAD 3-45 for individuals with preclinical AD—meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains—is ongoing. The study is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD) is also ongoing, with lecanemab serving as the backbone anti-amyloid therapy.

Dementia Prevalence in Canada

More than 770,000 people in Canada were estimated to be living with dementia in 2025, and that number is projected to increase to 1.7 million by 2050, according to the announcement. These figures highlight the growing need for effective treatments for Alzheimer's disease in Canada.

BioArctic, a Swedish biopharmaceutical company, noted that the information was released for public disclosure on September 1, 2026, at 07:00 CEST. The press release includes forward-looking statements that involve substantial risks and uncertainties, as is standard for such announcements.

How each outlet told it

A framing line is our reading of that outlet's own text — an interpretation, not a quotation and not a fact we assert. Check it against what the outlet published.

The Manila Times

Framing: Headline not captured, but the angle appears to be a promotion of a positive regulatory recommendation for LEQEMBI. — Promotional and positive, highlighting approvals and clinical trial progress.

as of Sep 1, 2026, 1:16 AM UTC

Facts Included:

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of LEQEMBI (lecanemab) for early Alzheimer's disease.
Lecanemab is the result of a collaboration between Eisai and BioArctic.
Lecanemab is an IgG1 monoclonal antibody directed against amyloid-beta.
Lecanemab has been approved in 53 countries and regions.
Lecanemab is under regulatory review in 6 countries.
The US FDA approved Eisai's BLA for subcutaneous maintenance dosing in August 2025.
Approval for subcutaneous maintenance dosing was obtained in the United States in July 2026.
In China, the application has been granted Priority Review designation.
Since December 2025, lecanemab (IV) has been included in the 'Commercial Insurance Innovative Drug List' introduced by the NHSA of China.
The Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD is ongoing since July 2020.
AHEAD 3-45 is a public-private partnership funded by the National Institute on Aging, Eisai and Biogen.
The Tau NexGen clinical study for Dominantly Inherited AD is ongoing since January 2022 and includes lecanemab as the backbone anti-amyloid therapy.
Biogen was founded in 1978.
Biogen uses different modalities to advance medicines.
The press release includes forward-looking statements with substantial risks and uncertainties.
LEQEMBI is approved in the US, Japan, China, Europe, South Korea, and Taiwan.

Read the source article →

PR Newswire UK

Framing: Positive and forward-looking, emphasizing an important step and next steps for access.

as of Sep 1, 2026, 6:46 AM UTC

Facts Included:

Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early AD).
The final recommendation follows a reconsideration by CDA-AMC.
Next steps include negotiations through the pan-Canadian Pharmaceutical Alliance.
More than 770,000 people in Canada were estimated to be living with dementia in 2025.
That number is projected to increase to 1.7 million by 2050.

Read the source article →

What was claimed, and who backed it

AI-extracted; can misattribute a claim — see Methodology.

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status is Contested when two claims on this page negate each other; otherwise it counts the distinct outlets we found asserting that specific claim — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimCanada's Drug Agency issued a final positive recommendation supporting public reimbursement of LEQEMBI (lecanemab) for early Alzheimer's disease.	ConfidenceHigh	StatusSingle-source via The Kingston Whig-Standard as of Aug 31, 2026, 7:45 PM UTC
ClaimLecanemab was developed through a strategic research alliance between Eisai and BioArctic.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC
ClaimLecanemab is an anti-amyloid-beta monoclonal antibody.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC, The Kingston Whig-Standard as of Aug 31, 2026, 7:45 PM UTC
ClaimLecanemab has been approved in 53 countries.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC
ClaimLecanemab is approved in 53 countries and under regulatory review in 6 countries.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC
ClaimThe US FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI in August 2025.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC
ClaimSubcutaneous initiation treatment (500 mg) was approved in the United States in July 2026.	ConfidenceHigh	StatusSingle-source via The Manila Times as of Sep 1, 2026, 1:16 AM UTC
ClaimThe recommendation is based on a review of clinical data including new 48-month data on continuous treatment with LEQEMBI.	ConfidenceHigh	StatusSingle-source via The Kingston Whig-Standard as of Aug 31, 2026, 7:45 PM UTC

Transparency & Audit Trail

2 distinct · 2 mastheads · 2 articles consulted: The Manila Times, PR Newswire UK 8 claims extracted Version 1 Written 2026-09-01